Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We have continued bid support for some reason, would be nice to know if we get PAOG shares.
Is Kaly in business or is this a shell at this time?
We have continued bid support for some reason, would be nice to know if we get PAOG shares.
Is Kaly in business or is this a shell at this time?
$kaly $0.0009 ? 0.0 (0.00%)
Volume: 2,014,790 @12/11/20 2:48:21 PM EST
etrade will not let you buy this crap .....call them you cant even trade it if you called them like you had to months ago to buy it.....
now etrade will not ,again will not let you buy kaly with your etrade account.
...every so often, the stock "pumpers" come back in an attempt to bring life back into a "pig".
Getting ready to take a ride. Are you riding with me?
A go what? A “go” scam and make it that this stock is worth something??
KALY is a go!
Should move soon with all the attention coming in
A small buying spree can rocket this one
Just let this run and let me out!!! lolol
Seems that someone is slowly eating up the stock between 1-1.3
Picking up the tax sellers that are taking the loss, and with the lack of news frustrated stockholders just saying f it.
Im guessing we will find out details in 2021????????
Seems that someone is slowly eating up the stock between 1-1.3
Picking up the tax sellers that are taking the loss, and with the lack of news frustrated stockholders just saying f it.
Im guessing we will find out details in 2021????????
Get ready for atleast a little run
Last official press release
Newsfile Corp.
July 16, 2020
This document corrects and replaces the press release that was issued by Kali Inc. (OTC Pink: KALY) (“KALY”) today July 16, 2020 at 11:24 am ET. The release below replaces the entirety of the previous release, as the incorrect release was sent.
The corrected press release follows in full below:
Dallas, Texas--(Newsfile Corp. - July 16, 2020) - Kali, Inc. (OTC Pink: KALY) ("KALY") today announced a deal in the works to sell its cannabis execration subsidiary, NCM Biotech, to PAO Group, Inc. (OTC Pink: PAOG) in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in a dividend distribution. The NCM Biotech sale marks an exit from the cannabis industry for KALY. The company has already developed a new business direction. The NCM Biotech sale to PAOG is expected to be complete by the end of July. KALY plans to announce its new business direction, which is already underway, in conjunction with the closing of the deal with PAOG.
Kaly...well on it's way to oblivion...
$kaly $0.0011 v -0.00004 (-3.51%)
Volume: 1,830,406 @11/18/20 3:57:44 PM EST
Good dam question.
I see no one ever answered this question....
yet inquiring minds would like to know. Anyone know how much KALI got from PAOG for RespRx?
$kaly $0.0011 ^ 0.0001 (10.00%)
Volume: 18,387,991 @11/09/20 2:52:14 PM EST
new contract I will believe it when I see it if its true then yes dollars for sure lets wait and see..i wont buy until news.
Take a look on this one...Volume and the PPS are surging! We will easily break the .002's before the close!
"Shareholders seemed to have been left wondering???"
That is an understatement.
$kaly $0.0012 ^ 0.0002 (20.00%)
Volume: 5,188,392 @10/23/20 3:59:09 PM EDT
It has been about 4 months now without a word. PURA seems to have gotten their stock. What is UP ? or Down ?
YOU THINK KALI IS LEGIT? READ THIS. https://www.thebasilelawfirm.com/post/sec-finally-going-after-toxic-convertible-note-debt-lenders
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158692654
Oooops - That should read March 28th 2019
Enjoy Pure and Total bliss thereafter.
CBD Central - We have BEAUTIFUL extracts.
The acquisition of RespRx is an all stock deal. PAOG has purchased RexpRx from KALY for common stock. PAOG remains in negotiations with KALY about a potential comprehensive acquisition of the underlying patent from which the RespRx formula was derived.
Has anyone received shares of PAOG yet?
Has anyone been informed of the new direction/business KALY announced after selling off respRx
Shareholders seemed to have been left wondering???
$kaly $0.00115 ^ 0.00005 (4.55%)
Volume: 609,166 @10/02/20 3:45:43 PM EDT
$kaly $0.001 v -0.0001 (-9.09%)
Volume: 700,000 @09/29/20 3:40:14 PM EDT
I need my PAOG shares, where can I get them?
KALY RAN OUT OF A SHACK IN AFRICA ON A SMALL ISLAND...
THEIR RAISE GOATS WHILE SELL BULL CHIT SHARES AND TAKE GOOD PEOPLES MONEY THIS PILE OF CHIT DOESNT EVEN HAVE AN OFFICE OR A PRODUCT ..
kaly was a pile of chit scam .its done they don't ever answer the phone or return emails, complete f ing fraud ....
they made their millions and left ....
just another pile of chit in penny land ..
The were a motor boat company before this. Lol
Kali, Inc. (OTC Pink: KALY) ("KALY") today announced a deal in the works to sell its cannabis execration subsidiary, NCM Biotech, to PAO Group, Inc. (OTC Pink: PAOG) in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in a dividend distribution. The NCM Biotech sale marks an exit from the cannabis industry for KALY. The company has already developed a new business direction. The NCM Biotech sale to PAOG is expected to be complete by the end of July. KALY plans to announce its new business direction, which is already underway, in conjunction with the closing of the deal with PAOG.
Any update if this deal closed? I Have not received any PAOG shares?
Does anyone know of the new business KALY is in?
PAOG Announces Analyst Report Update With $0.015 PPS 12-Month Target For New Cannabis Pharma Business
Source: InvestorsHub NewsWire
Sandusky, OH -- September 8, 2020 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC: PAOG) today announced Goldman Small Cap Research has published an analyst research report update. PAOG has recently entered the cannabis biopharmaceutical sector through two recent acquisitions. The company acquired a cannabis cultivation business from Puration, Inc. (PURA). From Kali-Extracts (KALY), PAOG acquired a proprietary CBD extract derived from a patented extraction process and formulated for the treatment of respiratory disorders.
Resized_Screenshot_20200908-183748_Gmail.jpg
The legislation, titled the “Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020,” would mandate that “cannabidiol derived from hemp, and any other ingredient derived from hemp shall be lawful under the Federal Food, Drug and Cosmetic Act (21 U.S.C. 301 et seq.) as a dietary ingredient in ...23 hours ago
000s end of the of month watch and learn ..
stop it their no company .....you should buy more many people got burned from these proven crooks do them a favor buy their shares.
show them ....too funny
Thank you so much for your tirelessly warnings for us gamblers about KALY garbage scam. I just wish I had your email so I could e-transfer you a boatload of money to show my appreciation when I make tons of money from other garbage scam stocks.
this company garbage ,call the number go to the address..
any extension you call will be busy . they will never call you back ....you wanna a good laugh go to the address....
these crooks do not anything period....it was a scam,
Followers
|
315
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
32923
|
Created
|
01/26/09
|
Type
|
Free
|
Moderators |
GOLDMAN SMALL CAP RESEARCH REPORT AUTHORIZED: 5,000,000,000 OUTSTANDING: 1,276,240,706 RESTRICTED: 255,174,312 UNRESTRICTED: 1,021,066,394
KALI'S NEW BUSINESS PLAN With the patented intellectual property (IP), to include the existing and ongoing research and development acquired from NCM Biotech, Kali will now concentrate on the development of pharmaceuticals to treat various illnesses, diseases and chronic pain as a symptom of various diagnoses. Kali will also concentrate on the development of health and wellness therapies. The cannabis pharmaceuticals market is forecasted to reach $50 billion in sales by 2029. The cannabis concentrates for wellness, edibles, and recreational markets is forecasted to reach $8.5 billion in annual sales by 2022. Prior to the acquisition by Kali, NCM Biotech was engaged with a number of different universities on a number of separate research initiatives. As an example, and as a preview of an upcoming announcement, NCM has been involved in an ongoing study with a university in Kentucky on the use of a cannabis therapy derived from Kali’s patented extraction process for the treatment of Chronic Obstructive Pulmonary Disease (COPD). A paper on the results of the study using Kali’s patented extraction process is anticipated to be published soon. NCM Biotech's medical advisory team includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children; Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs. Preclinical Research Study Results on Therapy for Respiratory Disease (COPD and Asthma) Below is a link to research recently conducted by Professor Jeffrey Osborn, President of Biomedical Science Research Group, LLC, and Biology Professor at the University of Kentucky Final Report for Pilot Study - NCMB-1 (aka Blue Dream)
LETTER TO SHAREHOLDERS FROM INCOMING CEO FREDERICK FERRI - NOVEMBER 27, 2018 Dear Kali Shareholders – |
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |